Skip to content Skip to main navigation

Pacritinib put on FDA hold

Published February 10, 2016.

The trial drug pacritinib (in development by CTI BioPharma) has been placed on full clinical hold by the FDA due to concerns over the safety of the drug. Analysis of data from clinical trials that were ongoing show a detrimental effect on survival and patient deaths from causes including intracranial hemorrhage, cardiac failure and cardiac arrest. This affects all pacritinib clinical trials. A full clinical hold means all patients currently on pacritinib must discontinue pacritinib immediately and no new patients can be enrolled in trials to receive pacritinib or can crossover from placebo.

Read article in Medscape

Read CTI BioPharma announcement

Stay up to date

Read the Canadian MPN Group newsletter for the latest in the field.

Watch Dr Vikas Gupta speak about Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era.

Download the new MPN eSimple app.

We need your help

The Canadian MPN Group relies on donor contributions to keep our work going. Can you help?

Twitter Feed